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Although Bordetella bronchiseptica can infect and colonize immunocompromised humans, its role as a
primary pathogen in pneumonia and other respiratory processes affecting those patients remains controver-
sial. A case of cavitary pneumonia caused by B. bronchiseptica in an AIDS patient is presented, and the basis
of the seemingly enhanced pathogenic potential of this isolate (designated 814) is investigated. B. bronchiseptica
was the only microorganism recovered from sputum, bronchoalveolar lavage fluid, and samples taken through
the protected brush catheter. Unlike previous work reporting the involvement of B. bronchiseptica in cases of
pneumonia, antibiotic treatment selected on the basis of in vitro antibacterial activity resulted in clearance of
the infection and resolution of the pulmonary infiltrate. Although isolate 814 produced reduced amounts of
several major antigens including at least one Bvg-activated factor (pertactin), the molecular basis of this
deficiency was found to be BvgAS independent since the defect persisted after the bvgAS locus of isolate 814 was
replaced with a wild-type bvgAS allele. Despite its prominent phenotype, isolate 814 displayed only a modest yet
a significant deficiency in its ability to colonize the respiratory tracts of immunocompetent rats at an early time
point. Interestingly, the antibody response elicited by isolate 814 in these animals was almost undetectable. We
propose that isolate 814 may be more virulent in immunocompromised patients due, at least in part, to its
innate ability to produce low amounts of immunogenic factors which may be required at only normal levels for
the interaction of this pathogen with its immunocompetent natural hosts.
Bordetella bronchiseptica, a small pleomorphic gram-nega-
tive coccobacillus, is a common upper respiratory tract patho-
gen in many domestic and wild animals and causes respiratory
diseases in a broad variety of mammal species such as cats,
dogs, horses, rabbits, and swine, among others (11). B. bron-
chiseptica synthesizes a wide array of virulence factors includ-
ing adhesins like filamentous hemagglutinin (FHA), fimbriae,
and pertactin and toxins like the bifunctional adenylate cyclase
toxin/hemolysin and tracheal cytotoxin (11). In B. bronchisep-
tica, like in other members of the Bordetella genus, a two-
component signal transduction system known as BvgAS con-
trols the expression of all protein virulence factors that have
been identified. When B. bronchiseptica grows at 37°C in the
absence of nicotinic acid or magnesium sulfate (modulating
agents), it expresses the so-called Bvg-positive (Bvg) phase,
characterized by the expression of virulence factors and the
repression of the flagellar apparatus, among other Bvg-re-
pressed phenotypes. B. bronchiseptica cells grown under Bvg-
phase conditions are fully virulent and nonmotile (1, 8). Con-
versely, incubation below 30°C or addition of modulating
agents to the culture medium inactivates BvgAS, thus simul-
taneously precluding protein virulence factor synthesis and
derepressing the flagellar apparatus and other Bvg-repressed
phenotypes. B. bronchiseptica cells grown under these condi-
tions (Bvg-phase conditions) are avirulent and motile (1, 8).
In contrast to this reversible transition, termed phenotypic
modulation, mutations leading to inactivation of BvgAS result
in an irreversible transition to the Bvg phase. Thus, this
genetic event, which occurs at a low frequency (106), gives
rise to avirulent Bvg-phase-locked mutants. The existence of
a tight correlation between phenotypic (Bvg) phase and viru-
lence has received further experimental confirmation with the
demonstration that mutants displaying phenotypically interme-
diate traits (locked in the so-called Bvgi phase) also exhibit an
intermediate ability to colonize the respiratory tracts of suit-
able hosts (9).
Reports of respiratory disease caused by B. bronchiseptica in
humans remain scarce and very rarely involve immunocompe-
tent patients (30) and more commonly involve children and
immunocompromised patients including, in many instances,
AIDS patients. For the last epidemiological group, isolation of
B. bronchiseptica from the respiratory tract (3, 6, 12, 13, 14, 17,
20, 23, 24, 32) or from the blood (26) of human immunodefi-
ciency virus (HIV)-infected patients with respiratory diseases
has been increasingly reported. This circumstance has
prompted some investigators to propose the inclusion of B.
bronchiseptica in the list of opportunistic pathogens causing
diseases associated with exposure of HIV-infected patients to
animals (20, 32). However, thus far the pathogenic role that B.
bronchiseptica plays in those processes has been difficult to
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ascertain since, in addition to B. bronchiseptica, other respira-
tory pathogens are usually coisolated from the respiratory
tracts of AIDS patients with pulmonary infections. Finally, to
assess the involvement of B. bronchiseptica in human respira-
tory diseases, it seems necessary to determine whether the
presence of specific phenotypic traits in certain B. bronchisep-
tica strains correlates with their pathogenic potential. To our
knowledge, this kind of information is lacking.
In this article we report on two cases of pulmonary disease
in AIDS patients differing in severity and clinical presentation
and make an evaluation of the pathogenic role of B. bronchi-
septica in the clinical processes.
CASE REPORTS
Patient 1. A 34-year-old woman was admitted to the Hospi-
tal Universitario Virgen del Rocío reporting a 2-week history
of cough with purulent expectoration, fever, and chills. In ad-
dition, she reported having lost 50% of her normal weight in
the previous 2 months. Four years earlier she had maintained
frequent heterosexual intercourse with an HIV-infected indi-
vidual. At the time of her admission, she owned a healthy dog.
On examination oropharyngeal thrush was observed and rales
in the left hemithorax were heard. The total leukocyte count
was 13,100/l, the hemoglobin concentration was 9.2 g/dl, and
the platelet count was 256,000/l. Serum electrolyte and cre-
atinine levels and liver enzyme levels were in the normal
ranges. The arterial partial oxygen pressure was 67 mm Hg, the
arterial partial carbon dioxide pressure was 39 mm Hg, and the
pH was 7.4. Detection of anti-HIV immunoglobulin G anti-
bodies first by enzyme immunoassay and then by Western
immunoblotting confirmed HIV infection. The CD4 lympho-
cyte count was 25/l, and HIV RNA levels were 1.5  106
copies/ml. A chest X ray showed an alveolar infiltrate with
areas of cavitation in the left upper lung lobe (Fig. 1). Micro-
scopic examination of sputum smears stained with either acid-
fast or Gram stain did not reveal the presence of any micro-
organism. Because of the suspicion of tuberculosis, isoniazid,
rifampin, and pyrazinamide were administered. Sputum cul-
tures exclusively yielded growth of B. bronchiseptica in pure
culture. This B. bronchiseptica clinical isolate was designated
814 and was sensitive to amikacin (MIC, 16 g/ml), amoxicil-
lin-clavulanic acid (MIC, 8/4 g/ml), ciprofloxacin (MIC, 1
g/ml), ofloxacin (MIC, 2 g/ml), gentamicin (MIC, 4 g/
ml), imipenem (MIC, 4 g/ml), tetracycline (MIC, 4 g/
ml), ticarcillin-clavulanic acid (MIC, 16 g/ml), and tobra-
mycin (MIC, 4 g/ml).
On the 8th day the patient remained febrile and bronchos-
copy was performed. Cultures of the samples obtained through
the protected brush catheter and bronchoalveolar lavage ex-
clusively yielded growth of 104 CFU of B. bronchiseptica with
the same antibiotic sensitivity as the organism recovered from
sputum. Treatment was switched to ofloxacin (400 mg oral
twice a day) on the 10th day. On the 20th day the patient was
asymptomatic, control cultures of sputum were negative, and
chest X ray showed progressive resolution of the infiltrate. On
the 28th day, the patient was discharged with antiretroviral
therapy consisting of stavudine, lamivudine, and indinavir. An-
timicrobial treatment was maintained for a total of 4 weeks.
Three months after admission the patient remained asymp-
tomatic, the CD4 cell counts were 250/l, the HIV RNA levels
were 70,000 copies/ml, and a control chest X ray appeared
normal.
Patient 2. A 26-year-old man who had been diagnosed with
AIDS and who had had Pneumocystis carinii pneumonia 2
months earlier was admitted to the Hospital Universitario Vir-
gen del Rocío with a 5-day history of cough, high fever, weight
loss, and left costal pain. He was a heroin addict and did not
report any contact with household, farm, or wild animals. The
physical examination disclosed fever (38.5°C), cachexia, tachy-
pnea, oral thrush, enlargement of the cervical lymph nodes,
and middle hepatomegaly. The rest of the physical examina-
tion was unremarkable. A chest X ray (not shown) revealed a
middle diffuse interstitial infiltrate. The total leukocyte count
was 10,500/l, the hemoglobin concentration was 10.6 g/dl, and
the platelet count was 364,000/l. Serum electrolyte and cre-
atinine levels and liver enzyme levels were in the normal
ranges. The arterial partial oxygen pressure was 67 mm Hg, the
arterial partial carbon dioxide pressure was 39 mm Hg, and the
pH was 7.4. The CD4 lymphocyte count was 97/l, and the
viral load was 338,623 copies/ml. Because of the initial suspi-
cion of P. carinii pneumonia, trimethoprim-sulfamethoxazole
treatment was started and the fever disappeared. Later, in a
computed tomography scan of the thorax, two noncavitating
nodules 5 cm in diameter were observed in both the left
lower and right upper lung lobes. Rhodococcus equi grew in the
blood cultures, and B. bronchiseptica was isolated from the
sputum culture. This B. bronchiseptica isolate was designated
222. Sputum cultures were negative for Legionella spp., myco-
bacteria, parasites, and fungi. A bronchoscopy was performed.
Only B. bronchiseptica (104 CFU) grew in the samples ob-
tained through the protected brush catheter and bronchoal-
FIG. 1. Chest X ray demonstrates cavitary pneumonia in patient 1.
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veolar lavage. The second B. bronchiseptica isolate recovered
from patient 2 was designated 629 and was sensitive to cipro-
floxacin (MIC, 1 g/ml), ofloxacin (MIC, 2 g/ml), amika-
cin (MIC, 16 g/ml), amoxicillin-clavulanic acid (MIC, 8/4
g/ml), gentamicin (MIC, 4 g/ml), imipenem (MIC, 4 g/
ml), tetracycline (MIC, 4 g/ml), ticarcillin-clavulanic acid
(MIC, 16 g/ml), and tobramycin (MIC, 4 g/ml) and was
resistant to co-trimoxazole (MIC, 2/38 g/ml). Trimethoprim-
sulfamethoxazole was discontinued; and vancomycin, rifampin,
and ciprofloxacin were administered for 15 days and the pa-
tient was discharged. One week before discharge the patient
quit the antimicrobial treatment. Two months later he was
admitted to the hospital with fever, cough, and chills. Chest X
ray and computed tomography scan images (not shown)
showed multiple bilateral nodules and an infiltrate in the left
lower lung lobe. R. equi was the only microorganism isolated
from blood cultures and samples obtained through bronchos-
copy.
MATERIALS AND METHODS
Identification of clinical isolates. Isolation of B. bronchiseptica from bron-
choalveolar lavage specimens was performed as follows. The bronchoalveolar
lavage fluid was diluted 1:10 and 1:100 prior to its inoculation on enriched blood
and chocolate agar plates. Only bronchoalveolar lavage fluid specimens render-
ing colony counts of at least 10,000 CFU/ml were considered positive and were
further processed. Clinical isolates were identified as B. bronchiseptica by using
combined sensitivity-identification panels (NEG Breakpoint Combo Type 15;
Dade International Inc., West Sacramento, Calif.) and miniature bacterial iden-
tification strips (API NE; bio Merieux, Marcy l’Etoile, France). Microscopic
examination of Gram-stained smears, extensive phenotypic characterization of
the isolates (see Table 1 and Fig. 3 and 4), and DNA sequencing of a portion of
the bvgS gene of isolate 814 supported the identification of the isolates as B.
bronchiseptica.
Bacterial strains and growth conditions. B. bronchiseptica strains RB50 and
RB54 were a kind gift of Peggy Cotter (Department of Molecular, Cellular and
Developmental Biology, University of California, Santa Barbara). These are
well-characterized strains that have been used in several studies on the interac-
tion of B. bronchiseptica with its natural hosts (2, 8, 9, 21). RB50 is a wild-type
strain isolated from the nares of a naturally infected rabbit. RB54 is a Bvg-
phase-locked derivative of RB50 (8). As positive or negative controls for some
biochemical determinations, human and ovine isolates of B. parapertussis (strains
12822 and Fr107, respectively [33]) were used. For the determination of hemo-
lytic activity and colony morphology, all the strains were grown on Bordet-
Gengou (BG) agar plates supplemented with 7.5% defibrinated sheep blood.
The plates were incubated at 37°C for 48 h. Motility assays were performed by
stabbing one medium-size colony in Stainer-Scholte (SS) medium (29) supple-
mented with 0.35% agar. The diameter of the motility halo was measured after
14 h of incubation at 37°C. When it was necessary to grow Bordetella under
Bvg-phase (modulating) conditions, nicotinic acid and MgSO4 were added to
the medium at final concentrations of 5 and 20 mM, respectively. Tyrosine agar
plates for determination of the browning activities of the strains were prepared
as described by Porter et al. (25). Whole-cell lysates for sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis (PAGE) analysis were prepared from
cells grown overnight in Luria-Bertani (LB) broth at 37°C with constant shaking.
To ensure the absence of Bvg-phase mutants in the liquid cultures, an aliquot
of each culture was plated on BG blood agar, and after 48 h of incubation at
37°C, the colonies were visually inspected for hemolytic activity.
SDS-PAGE, Western immunoblotting, and densitometry. SDS-PAGE was
performed as described previously (19, 22). Briefly, bacterial cells suspended in
phosphate-buffered saline (PBS) were lysed by the addition of 2 SDS-PAGE
sample buffer (27). Bacterial lysates were boiled for 5 min, stacked in an
SDS–4% polyacrylamide gel, and separated in an SDS–10% polyacrylamide gel.
Proteins were stained with Coomassie brilliant blue (27) or transferred to poly-
vinylidene difluoride membranes for immunoblotting. Proteins were probed with
either a 1:16,000 dilution of serum from a rat infected with B. bronchiseptica
RB50 (RA1 antiserum), a 1:2,500 dilution of antipertactin monoclonal antibody
(MAb) BPE3 (5), or a 1:2,000 dilution of serum from rats infected with either
one of the clinical isolates. Antigen-antibody complexes were detected with a
1:5,000 dilution of horseradish peroxidase-conjugated antibody of the appropri-
ate specificity (Amersham International, Little Chalfont, United Kingdom). The
immunocomplexes were detected by using an enhanced chemiluminescence as-
say (Amersham) according to the instructions of the manufacturer. Densitomet-
ric analysis was carried out on digitized images obtained with a high-resolution
scanner (JX 325; Sharp Corporation, Osaka, Japan) equipped with Amersham
Pharmacia ImageMaster software.
Experimental animals. Female Wistar rats were obtained from Harlan Spain
(Harlan Interfauna Iberica S.A., Barcelona, Spain) at 3 weeks of age. To confirm
that they were Bordetella-free, two animals of each lot were euthanatized and
samples of nasal, tracheal, and lung tissue were removed and cultured on BG
blood agar. Inocula were prepared from cells grown overnight in LB broth and
consisted of 1,000 CFU administered intranasally in 10 l of PBS while the
animals were slightly anesthetized by halothane inhalation. At the designated
time points postinoculation, the rats were anesthetized by halothane inhalation,
a sample of blood was obtained by cardiac puncture, and then the animals were
killed by cervical dislocation. The chest cavity was opened, and 1 cm of trachea
and the right lung lobes were removed and placed in PBS for homogenization.
The nose was dissected, and the entire nasal septum and the adjacent tissues
were removed and placed in PBS. Tissues were homogenized with tissue grind-
ers, and aliquots of the suspensions were plated on BG blood agar for determi-
nation of viable counts. Experimental data were analyzed by a two-way analysis
of variance test with SPSS software. Prior to this analysis, the interaction between
the parameters under investigation (animals of each group, strain type, site of the
respiratory tract) was confirmed to be nonsignificant. Animal protocols were
approved by the University of Navarra Animal Research Committee (protocol
number 039/00).
Hemagglutination and ELISAs. Hemagglutination activity was quantitated in
the supernatants of cultures grown in SS medium for 24 h at 37°C with constant
shaking. The hemagglutination assay has already been described (18).
Enzyme-linked immunosorbent assays (ELISAs) were performed as described
by Cotter and Miller (8) with slight modifications. Briefly, an overnight culture of
each B. bronchiseptica strain was adjusted to an optical density (600 nm) of 1.0
with LB broth, and the suspensions were diluted 1:10 in coating buffer (carbon-
ate-bicarbonate buffer [pH 9.7]) and sonicated. A total of 100 l of the suspen-
sion was added to each well, and the plates were incubated at 37°C for 2 h in a
humidified chamber and then overnight at 4°C. Nonspecific binding to the wells
was prevented by adding 150 l of 3% bovine serum albumin to each well and
incubating the plate for 60 min at 37°C. As the primary antibody, a 1:6,000
dilution of RA1 antiserum was added to the first well, twofold dilutions were
performed across eight wells, and the plates were incubated at 37°C for 60 min.
As the secondary antibody, horseradish peroxidase-conjugated anti-rat immuno-
globulin G antibody (Amersham) was used at a final concentration of 1:5,000.
The A405 was read after a 30-min incubation with the substrate 2,2-azinobis(3-
ethylbenzthiazoline sulfonic acid), purchased from Sigma.
PCR, cloning, and sequencing. Two oligonucleotides designed to anneal at
positions 2556 (GCTGGAATTCATGCGCGTGCTCA) and 3145 (CGATCTT
CGCAATGTCCAG), respectively, of the published B. bronchiseptica bvgAS
sequence were used as primers for the PCR. PCR was performed as follows: 3
mM MgCl2, 5% dimethyl sulfoxide, 1 U of Taq polymerase (Perkin-Elmer,
Wellesley, Mass.), the four deoxynucleoside triphosphates each at a concentra-
tion of 250 M, and 20 pmol of each primer were combined and brought to a
total volume of 25 l. A small portion of a colony was resuspended in the
solution as a source of template DNA. A Perkin-Elmer GeneAmp 2400 thermal
cycler was used for the reactions. The cycling parameters were as follows: incu-
bation at 95°C for 5 min, followed by 30 cycles of 95°C for 1 min, 55°C for 1 min,
and 72°C for 1 min and a final incubation at 72°C for 5 min. PCR products were
cloned into the pCR2.1 vector by using the TA cloning kit (Invitrogen, Carlsbad,
Calif.) according to the instructions of the manufacturer. Plasmids containing the
cloned PCR products were submitted for sequencing to Sistemas Genomicos,
S.L. (Paterna, Spain).
Construction of mutant strains by allelic exchange. The construction and
characteristics of plasmid PGMT8 have already been described (21). The entire
bvgAS locus of B. bronchiseptica 814 and adjacent sequences were deleted by
allelic exchange with plasmid pGMT8 to generate strain B. bronchiseptica 814-
DAS. B. bronchiseptica 814-DAS shares with RB55 the genetic configuration at
that chromosomal location and was constructed by the same method (21). PCR
analysis with primers designed to anneal at both sides of the deletion junction
resulted in the amplification of a fragment with the expected size, thus confirm-
ing that allelic exchange had occurred as intended. Plasmid pGMT40 carries a
chimeric bvgAS locus consisting of the whole bvgAS locus from B. bronchiseptica
RB50 except for the portion encoding part of the periplasmic BvgS domain. This
fragment was swapped with the equivalent segment from B. pertussis, and the
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resultant allele was shown to confer resistance to phenotypic modulation to B.
bronchiseptica (21). Plasmid pGMT40 was used to return a wild-type bvgAS locus
to strain B. bronchiseptica 814-DAS to generate B. bronchiseptica 814-P5. This
strain is equivalent to RB52-P5 and was constructed by the same method (21).
Construction of strains carrying lacZ fusions and quantitation of beta-galac-
tosidase activity. Plasmid pGMT18 carries an internal fragment of the pertactin
gene (prn) cloned upstream of a promoterless lacZ gene (21). Its integration into
the chromosome of Bordetella places the transcription of lacZ under the control
of the prn promoter. B. bronchiseptica strains carrying transcriptional fusions to
prn were constructed by using pGMT18 and by following a method that has been
already described. Beta-galactosidase activity was measured as described previ-
ously (21) in cells grown in SS medium to the mid-log phase. Statistical signifi-
cance was determined by using the Mann-Whitney test. To detect the occurrence
of spontaneous bvgAS mutants, aliquots from each broth with growth were plated
onto BG blood agar.
RESULTS
Rationale for the study and phenotypic analysis of the clin-
ical isolates. Compared to patient 2, patient 1’s respiratory
illness was more severe and could be attributed solely to in-
fection with B. bronchiseptica isolate 814, the only microorgan-
ism isolated from the respiratory tract of patient 1. Since both
the AIDS clinical stage and the immunological status of pa-
tient 2 did not significantly differ from those of patient 1, we
hypothesized that B. bronchiseptica 814 might be more patho-
genic than other B. bronchiseptica isolates including those re-
covered from patient 2 (isolates 222 and 629). To address this
hypothesis, we performed a comparative study of selected phe-
notypic characteristics of these three isolates. Specifically, we
focused on those phenotypes that are known to affect the
pathogenic potential of B. bronchiseptica.
Bearing in mind that the phenotypic phase of B. bronchisep-
tica closely correlates with its virulence, we first examined
whether all the clinical isolates were phenotypically wild-type
(virulent) or avirulent (bvg) variants. Wild-type strains, like B.
bronchiseptica RB50, grown on BG blood agar without modu-
lating agents give rise to small, domed, and hemolytic colonies,
while those of Bvgi-phase-locked mutants are slightly larger,
flatter, and less hemolytic. When modulating agents are added
to the medium or when Bvg is not functional (i.e., Bvg-phase-
locked mutants like B. bronchiseptica RB54) colonies appear
large, flat, and nonhemolytic. As shown in Table 1, all B.
bronchiseptica clinical isolates were phenotypically wild type
with respect to colony morphology and hemolysis. The ability
to regulate another prominent phenotype, motility, has been
shown to be of major importance for the pathogenicity of B.
bronchiseptica. Thus, mutants that cannot repress the flagellar
apparatus in the Bvg phase are unable to colonize the lower
respiratory tracts of rats (2). To determine whether any of the
clinical isolates had an altered pattern of regulation of motility,
all of the isolates were grown in SS medium with or without
modulating agents. As shown in Table 1, all the clinical isolates
exhibited a pattern of regulation of motility expected of a
wild-type B. bronchiseptica strain.
Experimental respiratory infection of rats. The ability of B.
bronchiseptica to colonize the respiratory tracts of susceptible
laboratory animals such as mice, rats, and rabbits has been
successfully exploited to compare the pathogenic potentials of
B. bronchiseptica strains in the context of a natural host-patho-
gen interaction. When delivered intranasally in a low-volume
(5- to 10-l) droplet of PBS, wild-type B. bronchiseptica strains
like RB50 efficiently colonize the rat and are recovered in high
numbers from the nose and the trachea and less consistently
from the lungs of the animal by day 14. A strong anti-Bordetella
antibody response is readily detectable by day 10. In sharp
contrast, avirulent mutants like RB54 are unable to colonize
any site of the respiratory tract even at the earliest time points
tested, while other mutants carrying less impairing mutations
display an intermediate level of virulence and are characteris-
tically unable to colonize the lower respiratory tract (2, 8, 9, 10,
21). We chose to use the rat model of respiratory infection to
detect potential differences in virulence among the clinical
isolates. As expected, at day 7 postinoculation RB54 was not
recovered from the respiratory tract of any rat. In contrast,
isolates 222 and 814 colonized the noses of all animals at a very
similar level and were recovered in similar numbers from the
lungs of two of five animals (Fig. 2). However, compared to
isolate 222, isolate 814 showed a reduced ability to colonize the
tracheas of the rats at day 7 postinoculation. This defect was
transient since at day 14 postinoculation this isolate was capa-
ble of establishing tracheal colonization at a level indistinguish-
able from those of the other isolates (data not shown). Animals










d Oxidased Citrated Nitrated Browninge
BG BG mod BG BG mod SS SS mod
RB50 8 sm/do la/fl     256   NDf ND 
814 PR1g sm/do la/fl     256     
222 PR2g sm/do la/fl     256     
629 PR2g sm/do la/fl     256 ND ND ND ND ND
RB54 8 la/fl la/fl     2   ND ND ND
12822 33 sm/do la/fl     ND     
Fr107 33 sm/do la/fl     ND     
a Colony morphology (sm/do, small and domed; la/fl, large and flat) and hemolytic activity were determined on BG blood agar without or with modulating (mod)
agents (nicotinic acid and MgSO4).
b Motility was determined in SS soft agar medium.
c FHA expression was determined in supernatants by hemagglutination (the titer is expressed as the maximal dilution at which positive hemagglutination was
detected).
d Activities were determined with miniature bacterial identification strips (API 20E).
e Browning activity was assessed on tyrosine agar plates.
f ND, not done.
g PR1 and PR2, patients 1 and 2 described in the present report, respectively.
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mock infected only with PBS remained Bordetella-free
throughout the experiment, and isolate 629 was recovered
from all sites of the respiratory tract in numbers similar to
those for isolate 222 and strain RB50 (data not shown). We did
not detect any macroscopic lesions in the respiratory tracts of
the animals or any outward sign of respiratory disease at any
time during the course of the infection.
Quantification of FHA production by the clinical isolates. A
derivative of strain RB50 carrying an in-frame deletion in the
gene encoding FHA has been shown to be unable to colonize
the lower respiratory tract of rats (10). Therefore, the reduced
ability of isolate 814 to colonize the trachea of rats could be the
result of a mutation leading to the deficient production or
secretion of FHA. To test this possibility, the amount of FHA
in the supernatants of overnight cultures of the isolates was
measured. As shown in Table 1, all clinical isolates produced
FHA at levels that were identical to those produced by RB50.
Characterization of clinical isolates by SDS-PAGE and
Western immunoblotting. To determine if the defect in colo-
nization exhibited by isolate 814 could result from the loss of
potentially antigenic virulence determinants, we compared the
antigenic profiles of all the isolates by Western immunoblot-
ting using serum from a rat infected with B. bronchiseptica
RB50 (RA1 antiserum). As shown in Fig. 3, while the antigenic
patterns of isolates 222 and 629 were nearly identical to that of
RB50, isolate 814 appeared to produce background levels of a
large number of antigens. This result was so striking that we
performed several control experiments to rule out any possible
experimental error. Thus, a second Western blot analysis with
a new whole-cell extract of isolate 814 gave similar results. In
addition, a duplicate gel was simultaneously run and subjected
to Coomassie brilliant blue staining to ensure that equivalent
amounts of protein had been loaded in all the gel lanes (Fig. 3).
Since the polypeptide profiles of all the isolates were almost
indistinguishable, the last experiment also indicated that the
difference in antigenic profiles detected by Western immuno-
FIG. 2. Colonization of the rat respiratory tract by B. bronchiseptica
clinical isolates. Wistar rats were inoculated intranasally with 10 l of
PBS containing 103 CFU of the indicated strains. The animals were
killed at day 7 postinoculation; and the numbers of CFU recovered
from the nasal turbinates, 1 cm of trachea, and the right lung lobes
were determined. Each symbol represents a single animal, bars repre-
sent the means, and the dotted line represents the lower limit of
detection. Statistical significance is designated with asterisks (one as-
terisk, P  0.05; two asterisks, P  0.01).
FIG. 3. Analysis of polypeptide and antigen expression in whole
cells of the B. bronchiseptica clinical isolates. (A and B) Whole-cell
lysates of the indicated strains were run in duplicate SDS-polyacryl-
amide gels and either stained with Coomassie brilliant blue (A) or
transferred to polyvinylidene difluoride membranes for immunoblot-
ting and probed with serum from a rat infected with B. bronchiseptica
RB50 (B). The positions of the molecular weight markers (in thou-
sands) are shown at the left. (C) Quantitation of total antigen expres-
sion by a whole-cell antigen-based ELISA. The same serum sample
used for panel B was used as the primary antibody.
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blotting was not due to a global deficiency in protein expres-
sion. Finally, to rule out potential experimental artifacts de-
rived from the gel transfer process, we performed ELISAs
using whole cells as the antigen and RA1 antiserum as the
primary antibody. As shown in Fig. 3, isolate 814 produced
background levels of the set of antigens detected by RA1
antiserum.
Isolate 814 expresses reduced levels of pertactin. Due to the
limited genetic diversity of B. bronchiseptica, it is highly un-
likely that an antiserum raised against a certain isolate will not
show strong cross-reactivity when it is used to probe a lysate of
any other B. bronchiseptica isolate. Nevertheless, to rule out
that RA1 antiserum was unable to recognize isolate 814 anti-
gens, we performed another comparative analysis of antigen
expression using an antibody of well-characterized specificity:
antipertactin MAb BPE3. This antibody was used to probe
whole-cell lysates of all the isolates by Western immunoblot-
ting, and then the levels of pertactin were quantitated by den-
sitometry. While the amounts of pertactin expressed by isolates
222 and 629 were very similar to those expressed by RB50,
isolate 814 expressed less than one-third of that amount (Fig.
4). In addition, the apparent molecular weight of the band
detected in the lysate of isolate 814 was slightly higher than
that of the rest of the isolates (approximately 70,000 versus
68,000) and matched the molecular weight reported for the B.
parapertussis pertactin. Although B. bronchiseptica strains ex-
pressing pertactin isotypes with the same molecular weight as
that of the B. parapertussis pertactin have recently been iso-
lated (4), we performed an additional test to confirm that
isolate 814 was indeed a B. bronchiseptica isolate rather than an
unusual B. parapertussis isolate. As shown in Table 1, isolate
814 behaved as a typical B. bronchiseptica strain because, un-
like human isolates of B. parapertussis, it was oxidase positive,
was motile, grew using citrate as the only carbon source, was
able to reduce the nitrates to nitrites, and did not produce
browning on tyrosine agar. Isolate 814 also differed from ovine
isolates of B. parapertussis in several of these characteristics.
The epitope recognized by MAb BPE3 has already been iden-
tified (7), and we confirmed that it is unaltered in all the known
pertactin isotypes regardless of their molecular weight.
Analysis for the presence of Bordetella-specific DNA se-
quences in isolate 814. To provide more solid evidence that
isolate 814 was indeed a B. bronchiseptica isolate, we decided
to analyze the isolate for the presence of B. bronchiseptica-
specific DNA sequences. To do that we constructed primers
designed to amplify by PCR a 600-bp DNA fragment encom-
passing the linker-encoding sequences and some of the trans-
mitter-encoding sequences of bvgS. A unique PCR product of
the expected size was amplified, cloned, and sequenced by
using chromosomal DNA from isolate 814. A search with the
BLAST program and the deduced amino acid sequence re-
vealed that the amplified region is 99% identical to the B.
bronchiseptica sequence available in GenBank. Compared to
the published BvgS amino acid sequence, we found that the
sequence of isolate 814 contains 2 amino acid changes (Met-
650-Val and Val-677-Ile) over a stretch of 201 amino acids and
that both of these substitutions are conservative.
Quantification of the transcriptional activity of a Bvg-acti-
vated gene in the clinical isolates. Since prn is transcriptionally
activated by the BvgAS signal transduction system, the reduced
level of expression of pertactin observed in isolate 814 could be
due to a global decrease in BvgAS activity in this isolate. If so,
this potential decrease would also affect the expression of
other Bvg-activated factors, thus causing an overall reduction
in the level of protein expression such as that observed in
isolate 814. To test this hypothesis we constructed derivatives
of isolates 222 and 814 carrying a promoterless lacZ operon
transcriptionally fused to prn and compared the levels of pro-
duction of beta-galactosidase in the lacZ fusion strains grown
under Bvg-phase conditions. The results of three indepen-
dent experiments performed in triplicate indicate that the ac-
tivity of the prn promoter in isolate 814 (mean, 1,692.24 units;
standard deviation, 827 units) is approximately 5 times lower
than that of isolate 222 (mean, 8,123.75 units; standard devia-
tion, 2,110 units). Statistical analysis revealed that this differ-
ence was very significant (P  0.01).
Comparative analysis of the immune responses of rats in-
fected with the clinical isolates. We hypothesized that whereas
B. bronchiseptica may require expression of wild-type levels of
antigens involved in virulence for the colonization of healthy
immunocompetent hosts, this pathogen may not need to ex-
press antigens at those levels for its interaction with immuno-
compromised patients. Under those circumstances the lack of
FIG. 4. Expression of pertactin in whole cells of the B. bronchisep-
tica clinical isolates. Whole-cell lysates of the indicated strains were
run in duplicate SDS-polyacrylamide gels and either stained with Coo-
massie brilliant blue (A) or transferred to polyvinylidene difluoride
membranes for immunoblotting and probed with antipertactin MAb
BPE3 (B). Band sizes were determined by densitometry and are ex-
pressed in units of optical density  millimeter2 with respect to a
calibrated standard. The positions of the molecular weight markers (in
thousands) are shown at the left.
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expression of several major B. bronchiseptica antigens might
not be detrimental, and it might even be advantageous for the
pathogen if the lack of expression led to inefficient recognition
by the immune system. That could precisely be one of the
mechanisms enabling isolate 814 to cause a more severe pa-
thology in immunocompromised humans. To test this hypoth-
esis we compared the antibody response induced by experi-
mental infection with isolate 222 with that brought about by
infection with isolate 814. Figure 5 shows the results from a
representative experiment. Whereas rats infected with isolate
222 mounted a prominent anti-B. bronchiseptica-specific anti-
body response at day 14 postinoculation, the antibody response
elicited by isolate 814 in rats was almost undetectable at the
same time point. This difference in immunogenicity between
the clinical isolates was long lasting, as revealed by comparison
of the antibody responses induced by the isolates at a later time
point (49 days) postinoculation (Fig. 5). A longer (fivefold)
exposure of the films revealed the presence of faint bands in
the membranes incubated with serum from animals infected
with isolate 814 (data not shown), indicating that the experi-
ment was technically performed as intended. As expected, sera
collected both from animals before inoculation and from
mock-infected animals at the final experimental time point
were confirmed to be devoid of anti-B. bronchiseptica-specific
antibodies (data not shown).
Replacement of the bvgAS locus of isolate 814 with a wild-
type bvgAS allele. To study the role of the BvgAS system in the
phenotype exhibited by isolate 814, we decided to replace its
bvgAS locus with a wild-type bvgAS allele and characterize the
phenotype of the recombinant strain. To do that, we first de-
leted the entire bvgAS locus of isolate 814 and adjacent regions
by allelic exchange, thus generating strain 814-DAS. PCR anal-
ysis (see Material and Methods) revealed that the chromo-
somal configuration of strain 814-DAS at the deletion site had
the intended arrangement (data not shown) We then ex-
changed the deletion allele present in strain 814-DAS with the
wild-type bvgAS allele carried by plasmid pGMT40, which con-
fers resistance to modulation. As a proof that the exchange had
taken place as intended, we confirmed that the resultant strain
(814-P5) had lost the sensitivity to modulation characteristic of
isolate 814 and had become resistant to modulation. Contrary
to our expectations, Western blot analyses with either RA1
antiserum or antipertactin MAb BPE3 repeatedly failed to
show any quantitative or qualitative difference in protein ex-
pression between strain 814-P5 and its isogenic parental strain
(data not shown).
DISCUSSION
We found 11 reports in the English-language literature de-
scribing the isolation of B. bronchiseptica from 15 cases of
infectious processes affecting AIDS patients (3, 6, 12, 13, 14,
17, 20, 23, 24, 26, 32). The patients are usually in an advanced
stage of HIV infection and in some cases have had contact with
pets. Clinical presentation is acute or subacute and includes
fever and respiratory symptoms. In most cases, chest X-ray
images show interstitial infiltrates that make the physician con-
sider the involvement of pathogens other than B. bronchisep-
tica. Etiological diagnosis often requires the retrieval of respi-
ratory samples by bronchoscopy (through bronchoalveolar
lavage or a protected brush catheter). The concomitant isola-
tion of other microorganisms from six patients hampered the
evaluation of the pathogenic role of B. bronchiseptica in the
respiratory processes in those patients. This fact is more evi-
dent considering that four of the patients were cured with
specific treatment against the pathogens concomitantly iso-
lated (24). On the other hand, it has been emphasized that a
poor correlation exists between the results of antibiogram tests
and the clinical response to the antimicrobial regimen selected.
In fact, the first specific treatment failed for three of the pa-
tients, and one patient died, even though the vitro activity of
the antimicrobial treatment used was adequate (3, 20, 24).
Treatment duration is also a controversial issue. It varies from
2 to 4 weeks for patients with a good response (3, 12, 13, 20, 23,
32) to 6 months for patients with recurrent symptoms (24). The
increasing rate of isolation of B. bronchiseptica from AIDS
patients with pneumonia emphasizes its importance as an op-
portunistic pathogen and guarantees the consideration of B.
bronchiseptica as a potential etiological agent of pneumonia
with or without lung cavitation in AIDS patients.
Some aspects of the present study are worth mentioning.
First, to our knowledge there has been only one report (14)
describing lung cavitation as the clinical presentation of pneu-
monia caused by B. bronchiseptica in an HIV-infected patient.
This patient, like patient 1 in the present study, was first mis-
takenly diagnosed with tuberculosis and was consequently
treated with tuberculostatic agents. Second, the isolation of B.
bronchiseptica without the concomitant isolation of other
pathogens and the good clinical evolution observed for patient
1 after specific antimicrobial treatment indicate that B. bron-
chiseptica isolate 814 was the causative agent of patient 1’s
cavitary pneumonia. To the contrary, all the clinical data sug-
gest that B. bronchiseptica infection was not the primary etio-
logical factor in patient 2’s respiratory process.
In this work we show that isolate 814 produces reduced
FIG. 5. Western immunoblot of RB50 whole-cell lysate antigen
probed with serum from rats infected with isolate 222 or isolate 814.
Lanes 1, 3, and 5, serum from different rats infected with isolate 222 for
either 14 days (lanes 1 and 3) or 49 days (lane 5); lanes 2, 4 and 6,
serum from different rats infected with isolate 814 for either 14 days
(lanes 2 and 4) or 49 days (lane 6). The positions of the molecular
weight markers (in thousands) are shown at the left.
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amounts of a large number of antigens including pertactin.
Consistent with the low level of expression of pertactin, our
results demonstrate that the level of transcription driven by the
prn promoter is greatly reduced in isolate 814. It seems likely
that this decrease in transcriptional activity may cause, at least
in part, the deficient expression of pertactin observed in isolate
814. However, the fact that the levels of expression of antigens
including pertactin were not restored after exchange of the
bvgAS locus with a wild-type bvgAS allele indicates that other
(BvgAS-independent) mechanisms must also be impaired in
this isolate. If these mechanisms, as our results suggest, act at
the translational or postranslational level, that would explain
why they seem to be dominant over the mere transcriptional
activity mediated by BvgAS. Precisely because of this effect,
our results do not allow us to draw a conclusion as to whether
the bvgAS locus of isolate 814 is fully functional. Whatever the
molecular basis of the phenotype displayed by isolate 814 is, it
seems to affect the expression of its virulence determinants to
different degrees. Thus, while the level of expression of per-
tactin is reduced in this isolate, the production of FHA seems
to be unaffected. Interestingly, it has very recently been de-
scribed that deep rough mutants of B. bronchiseptica express
reduced levels of pertactin and other Bvg-activated factors
(28). Moreover, like isolate 814, these B. bronchiseptica rough
variants were originally isolated from a patient with pneumo-
nia (15). However, unlike isolate 814, deep rough B. bronchi-
septica mutants also express reduced levels of FHA. We are
investigating whether isolate 814 carries mutations leading to
expression of an altered lipopolysaccharide.
The reduced levels of antigen production exhibited by iso-
late 814 may suffice to explain why this isolate was defective for
the colonization of the trachea of the rat, which is one of the
natural hosts of B. bronchiseptica. In fact, it has been shown
that B. bronchiseptica mutants expressing intermediate levels of
several virulence determinants are unable to colonize the
lower respiratory tract of rats (9). However, the experimental
hosts used for B. bronchiseptica in the present investigation
were immunocompetent animals. Therefore, the inability of
isolate 814 to efficiently colonize them may not reflect the
pathogenic potential of this isolate in an immunocompromised
host like patient 1. In support of this notion, it has recently
been shown that a B. bronchiseptica rough mutant colonizes the
respiratory tract of immunocompromised mice as efficiently as
its wild-type isogenic strain, whereas it exhibits a reduced abil-
ity to colonize the lower respiratory tract of immunocompetent
animals compared to that of the wild-type strain (16).
Our results indicate that, despite its prominent defect, iso-
late 814 not only was able to colonize the respiratory tract of
patient 1 but also caused a respiratory pathology more severe
than that brought about by other B. bronchiseptica isolates
including isolate 222. This behavior, which is totally unex-
pected from a seemingly defective strain, led us to hypothesize
that isolate 814 might have a selective advantage for the col-
onization of an immunocompromised host. In support of this
hypothesis, our results show that isolate 814 elicits an almost
undetectable antibody response even when colonizing an im-
munocompetent host. In light of patient 1’s immunocompro-
mised condition, it is very likely that her immune response
against isolate 814 was even weaker. Interestingly, it has been
shown that the clinical outcome of pneumonia caused by an
opportunistic pathogen in HIV-infected patients was more se-
vere in subjects who had low levels of specific antibodies,
whereas patients who recovered had elevated specific antibody
levels over time (31). Nevertheless, to test our hypothesis it
would have been necessary to quantitate the anti-B. bronchi-
septica-specific antibodies in patient 1’s serum; unfortunately,
however, no more serum could be obtained for this purpose.
Finally, for isolate 814, reduced levels of expression of antigens
could have the additional advantage of relieving it from the
metabolic burden involved in synthesizing wild-type amounts
of a large number of polypeptides. While such a strain would
be counterselected in an immunocompetent host, its superior
growth capability may turn out to be advantageous in an im-
munocompromised host. In agreement with this hypothesis,
significant reductions in the doubling times of both B. bronchi-
septica and B. pertussis have been observed when isolates of
these species are grown under conditions that favor even a
slight decrease in the production of Bvg-phase-specific anti-
gens (e.g., under Bvgi-phase conditions) (G. Martinez de
Tejada, unpublished observations).
To draw a more complete picture of the features enabling B.
bronchiseptica to cause severe respiratory diseases in immuno-
compromised humans, it seems necessary to characterize a
collection of isolates recovered from patients with similar pa-
thologies (i.e., cavitary pneumonia). Such a broad analysis will
be possible when a relevant number of cases similar to the one
reported here come to light. However, the following conclu-
sion can be extracted from our study: appearances can be
deceptive when predicting the pathogenic potential in immu-
nocompromised humans of a B. bronchiseptica isolate display-
ing a major defect in protein expression involving at least one
virulence factor. In fact, if that defect could be proven to result
in enhanced virulence, this would be, to our knowledge, the
first report suggesting that what makes a B. bronchiseptica
isolate defective for the colonization of one particular host may
constitute an adaptive advantage for the colonization of an-
other one.
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